These findings have led to the development of a screening tool, termed polycystic ovary syndrome-hepatic steatosis (PCOS-HS) index, which incorporates body mass index (BMI) percentile, waist circumference, alanine aminotransferase (ALT), and sex hormone-binding globulin (SHBG) to assess the risk of MASLD in obese adolescents affected by PCOS [16]. This evidence concerns the gene GPT and polycystic ovary syndrome.